177Lu XT117 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be a solid tumor that has been confirmed by a biopsy.
- Standard treatments must have failed or not be available for you.
- A special PET scan must show that your tumor has a target called FAP.
- You must be in good enough health to do daily activities (ECOG 0 or 1).
- You cannot have serious heart problems, uncontrolled diabetes, or other active cancers (except minor ones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests a new drug that targets tumors with a specific marker you can see on a PET scan. It is for people whose cancer has spread or come back after standard treatments, and it may help shrink tumors or slow their growth.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial is testing an investigational drug called 177Lu-FAP-VG1 for people with advanced solid tumors that have stopped responding to standard therapy. The drug is a type of radiation therapy that targets a protein called FAP, which is found on many cancer cells, to try to shrink the tumor and slow the cancer's growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.